Background: Many inflammatory and haemostatic biomarkers show associations with acute ischaemic stroke outcome, but few studies compare a large range of markers. Methods: We assessed clinical status and 16 biomarkers within 24 h of onset in 180 consecutive acute ischaemic stroke patients. Results: A total of 94 patients had a poor outcome (dead or dependent at 30 days). C-reactive protein (CRP), IL-6, and fibrin D-dimer showed the strongest univariate associations with poor outcome (>2-fold increase; p < 0.01). When all biomarkers were included with clinical variables in a multivariable model, only D-dimer (OR 1.54; 95% CI 1.09–2.17), CRP (OR 1.31; 95% CI 1.03–1.68) and Scandinavian Stroke Scale (OR 0.91; 95% CI 0.88–0.95) were associated with poor outcome. Conclusions: D-dimer and CRP are independently associated with poor outcome in acute ischaemic stroke. More data is required to expand our understanding of these potential relationships with outcome.

Keywords:
Inflammation, Haemostasis, Ischaemic stroke, Risk markers
1.
Lowe GD: Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J Thromb Haemost 2005; 3:1618–1627.
2.
Matijevic N, Wu KK: Hypercoagulable states and strokes. Curr Atheroscler Rep 2006;8:324–329.
3.
Fibrinogen Studies Collaboration: Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005;294:1799–1809.
4.
Di Napoli M, Schwaninger M, Cappelli R, Ceccarelli E, Di Gianfilippo G, Donati C, Emsley HC, Forconi S, Hopkins SJ, Masotti L, Muir KW, Paciucci A, Papa F, Roncacci S, Sander D, Sander K, Smith CJ, Stefanini A, Weber D: Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke 2005;36:1316–1329.
5.
Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB, Wensley F, Higgins JP, Lennon L, Eiriksdottir G, Rumley A, Whincup PH, Lowe GD, Gudnason V: Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008;5:e78.
6.
Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, Rupprecht HJ; AtheroGene Investigators: Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002;106:24–30.
7.
Blankenberg S, Luc G, Ducimetiere P, Arveiler D, Ferrieres J, Amouyel P, Evans A, Cambien F, Tiret L: Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2003;108:2453–2459.
8.
Koenig W, Khuseyinova N, Baumert J, Thorand B, Loewel H, Chambless L, Meisinger C, Schneider A, Martin S, Kolb H, Herder C: Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984–2002. Arterioscler Thromb Vasc Biol 2006;26:2745–2751.
9.
Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E: Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000;101:2149–2153.
10.
Koukkunen H, Penttila K, Kemppainen A, Halinen M, Penttila I, Rantanen T, Pyorala K: C-reactive protein, fibrinogen, interleukin-6 and tumor necrosis factor-alpha in the prognostic classification of unstable angina pectoris. Ann Med 2001;33:37–47.
11.
Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB, Pahor M: Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003;108:2317–2322.
12.
Di Napoli M, Papa F, Bocola V: Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke 2001;32:133–138.
13.
Turaj W, Slowik A, Dziedzic T, Pulyk R, Adamski M, Strojny J, Szczudlik A: Increased plasma fibrinogen predicts one-year mortality in patients with acute ischemic stroke. J Neurol Sci 2006;246:13–19.
14.
Di Napoli M, Papa F, Bocola V: C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke 2001;32:917–924.
15.
Anuk T, Assayag EB, Rotstein R, Fusman R, Zeltser D, Berliner S, Avitzour D, Shapira I, Arber N, Bornstein NM: Prognostic implications of admission inflammatory profile in acute ischemic neurological events. Acta Neurol Scand 2002;106:196–199.
16.
Di Napoli M, Papa F: Should neurologists measure fibrinogen concentrations? J Neurol Sci 2006;246:5–9.
17.
Montaner J: Stroke biomarkers: can they help us to guide stroke thrombolysis? Drug News Perspect 2006;19:523–532.
18.
Di Napoli M, Papa F; Villa Pini Stroke Data Bank Investigators: Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first ever ischemic stroke patients. Stroke 2002;33:1763–1771.
19.
Welsh P, Lowe GD, Chalmers J, Campbell DJ, Rumley A, Neal BC, Macmahon SW, Woodward M: Associations of proinflammatory cytokines with the risk of recurrent stroke. Stroke 2008;39:2226–2230.
20.
Barber M, Langhorne P, Rumley A, Lowe GD, Stott DJ: Hemostatic function and progressing ischemic stroke: D-dimer predicts early clinical progression. Stroke 2004;35:1421–1425.
21.
Ageno W, Finazzi S, Steidl L, Biotti MG, Mera V, Melzi D’Eril G, Venco A: Plasma measurement of D-dimer levels for the early diagnosis of ischemic stroke subtypes. Arch Intern Med 2002;162:2589–2593.
22.
Berge E, Friis P, Sandset PM: Hemostatic activation in acute ischemic stroke. Thromb Res 2001;101:13–21.
23.
Barber M, Morton JJ, Macfarlane PW, Barlow N, Roditi G, Stott DJ: Elevated troponin levels are associated with sympathoadrenal activation in acute ischaemic stroke. Cerebrovasc Dis 2007;23:260–266.
24.
Welsh P, Woodward M, Rumley A, Lowe G: Associations of plasma pro-inflammatory cytokines, fibrinogen, viscosity and C-reactive protein with cardiovascular risk factors and social deprivation: the fourth Glasgow MONICA study. Br J Haematol 2008;141:852–861.
25.
Franchini M: Hemostasis and aging. Crit Rev Oncol Hematol 2006;60:144–151.
26.
Smith CJ, Emsley HC, Vail A, Georgiou RF, Rothwell NJ, Tyrrell PJ, Hopkins SJ: Variability of the systemic acute phase response after ischemic stroke. J Neurol Sci 2006;251:77–81.
27.
Lip GY, Blann AD, Farooqi IS, Zarifis J, Sagar G, Beevers DG: Sequential alterations in hemorheology, endothelial dysfunction, platelet activation and thrombogenesis in relation to prognosis following acute stroke: The West Birmingham Stroke Project. Blood Coagul Fibrinolysis 2002;13:339–347.
28.
Zaremba J, Losy J: Interleukin-18 in acute ischemic stroke patients. Neurol Sci 2003;24:117–124.
29.
Wheeler RD, Boutin H, Touzani O, Luheshi GN, Takeda K, Rothwell NJ: No role for interleukin-18 in acute murine stroke-induced brain injury. J Cereb Blood Flow Metab 2003;23:531–535.
30.
Stuyt RJ, Netea MG, Verschueren I, Dinarello CA, Kullberg BJ, van der Meer JW: Interleukin-18 does not modulate the acute-phase response. J Endotoxin Res 2005;11:85–88.
31.
Zaremba J, Losy J: Early TNF-alpha levels correlate with ischaemic stroke severity. Acta Neurol Scand 2001;104:288–295.
32.
Vila N, Castillo J, Davalos A, Chamorro A: Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000;31:2325–2329.
33.
Emsley HC, Smith CJ, Gavin CM, Georgiou RF, Vail A, Barberan EM, Hallenbeck JM, del Zoppo GJ, Rothwell NJ, Tyrrell PJ, Hopkins SJ: An early and sustained peripheral inflammatory response in acute ischemic stroke: relationships with infection and atherosclerosis. J Neuroimmunol 2003;139:93–101.
34.
Smith CJ, Emsley HC, Gavin CM, Georgiou RF, Vail A, Barberan EM, del Zoppo GJ, Hallenbeck JM, Rothwell NJ, Hopkins SJ, Tyrrell PJ: Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol 2004;4:2.
35.
Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V: Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000;148:209–214
36.
Lowe GD, Rumley A, McMahon AD, Ford I, O’Reilly DS, Packard CJ; West of Scotland Coronary Prevention Study Group: interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol 2004;24:1529–1534.
37.
Montaner J, Perea-Gainza M, Delgado P, Ribó M, Chacón P, Rosell A, Quintana M, Palacios ME, Molina CA, Alvarez-Sabín J: Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke 2008;39:2280–2287.
38.
Squizzato A, Ageno W, Finazzi S, Mera V, Romualdi E, Bossi A, Venco A: D-dimer is not a long-term prognostic marker following acute cerebral ischemia. Blood Coagul Fibrinolysis 2006;17:303–306.
39.
Weir NU, Gunkel A, McDowall M, Dennis MS: Study of the relationship between social deprivation and outcome after stroke. Stroke 2005;36:815–819.
40.
Wong KY, Wong SY, Fraser HW, Ersoy Y, Ogston S, Wolfson D, Malek M, Struthers AD, Tunstall-Pedoe H, MacWalter RS: Effect of social deprivation on mortality and the duration of hospital stay after a stroke. Cerebrovasc Dis 2006;22:251–257.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.